Sorrento To Start Testing STI-3031 In Patients With Advanced Urothelial Carcinoma

  • The FDA has signed off Sorrento Therapeutics Inc's SRNE IND to proceed with a Phase 2a study for STI-3031 for advanced urothelial carcinoma.
  • STI-3031 is based on Sorrento's G-MAB library that has fostered the development of several oncology programs currently in Phase 2 and Phase 3 clinical trials and neutralizing mAbs currently in Phase 2 trial directed against the spike protein of COVID-19 viruses.
  • STI-3031, also known as IMC-001, was licensed to ImmuneOncia Therapeutics Inc a joint venture between Sorrento and Yuhan Corporation.
  • The candidate has completed a Phase 1b study in patients with metastatic or locally-advanced solid tumors and is nearing completion of Phase 2 study in patients with resectable gastric cancer, esophageal cancer, and liver cancer.
  • ImmuneOncia has also started to enroll patients in a Phase 2 study in relapsed or refractory extranodal NK/T cell lymphoma.
  • A second antibody, Socazolimab, is licensed to Lee's Pharmaceutical Holdings Limited in the Greater China territory and has been cleared to begin a multicenter Phase 3 trial as a potential first-line treatment for patients with extensive-stage small-cell lung cancer.
  • Price Action: SRNE shares are up 3.45% at $8.69 during the market trading session on the last check Tuesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsHealth CareFDAGeneralPhase 2 TrialUrothelial CancerUrothelial Carcinoma
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!